Contemporary Cardiology™ Khan Series Editor: Christopher P. Cannon, MD • Executive Editor: Annemarie M. Armani, MD Cardiac Cardiac Cardiac Drug Therapy S E EVENTH DITION M. Gabriel Khan, MD, FRCP(LONDON), FRCP(C), FACP, FACC CC Associate Professor of Medicine, University of Ottawa; Cardiologist, The Ottawa Hospital, Ottawa, Ontario, Canada Drug Drug aa rr Cardiac Drug Therapy, 7th ed., addresses the pharmacology and therapeutic application of drugs used to dd treat heart diseases and hypertension. Additions and updates to the sixth edition include six new chapters on ii current controversies in cardiac drug therapy such as the beta blocker issue many cardiologists are presently aa Therapy grappling with. The book provides practical advice on how to manage cardiac diseases and addresses the Therapy cc choice of one particular cardiac agent vs. another. In addition to providing core knowledge in cardiovascular therapeutics, the text assists in resolving some of the issues surrounding cardiac drugs. Cardiac Drug Therapy DD provides practical information including properties, dosage, side effects, potential salutary benefits, and drawbacks on virtually all commercially available cardiac drugs. The text is succinct and straightforward, and rr highlighted throughout with bullet points that enable rapid-retrieval of clinically relevant information. uu SS EE gg EEVVEENNTTHH DDIITTIIOONN Features TT • Updates and revises the sixth edition • Provides quick reference to drug therapies available for every type of cardiovascular disease • Includes six new chapters that deal with hh ongoing controversies regarding the use • Includes expanded drug administration and dosage of several widely used drugs tables, new material on results of clinical trials ee MM.. GGaabbrriieell KKhhaann • Discusses the beta-blocker and ACE • Features the current guidelines from the American rr inhibitor controversies College of Cardiology (ACC) on cardiac arrest aa pp MMDD,, FFRRCCPP((LLOONNDDOONN)),, FFRRCCPP((CC)),, FFAACCPP,, FFAACCCC Contents yy Beta-Blockers: The Cornerstone of Cardiac Drug Infarction. Management of Heart Failure. Heart Failure Therapy. Beta-Blocker Controversies. Angio- Controversies. Management of Cardiac Arrhythmias. tensin-Converting Enzyme Inhibitors and Cardiac Arrest. Management of Infective Endocarditis. Angiotensin II Receptor Blockers. ACE Management of Dyslipidemias. Statin Controversies. Inhibitor Controversies. Calcium Antagonists Antiplatelet Agents, Anticoagulants, Specific Thrombin (Calcium Channel Blockers). Calcium Antago- Inhibitors. Cardiac Drugs During Pregnancy and Lacta- nists Controversies. Diuretics. Hypertension. tion. Effects of Drug Interactions. Hallmark Clinical Hypertension Controversies. Management of Trials. Appendices. Index. Angina. Management of Acute Myocardial Seventh Edition Contemporary Cardiology™ CARDIAC DRUG THERAPY SEVENTH EDITION ISBN: 978-1-58829-904-8 E-ISBN: 978-1-59745-238-0 humanapress.com C D T ARDIAC RUG HERAPY C C ONTEMPORARY ARDIOLOGY CHRISTOPHER P. CANNON, MD SERIES EDITOR ANNEMARIE M. ARMANI, MD EXECUTIVE EDITOR Nuclear Cardiology: The Basics: How to Set Up Diabetes and Cardiovascular Disease, Second and Maintain a Laboratory, Second Edition, Edition, edited by Michael T. Johnstone, MD, CM, by Frans Wackers, MD, PhD, Barry L. Zaret, FRCP(C), and Aristidis Veves, MD, DSc, 2005 MD, PhD, and Wendy Bruni, CNMT, 2008 Angiogenesis and Direct Myocardial Revascular- Rapid ECG Interpretation, Third Edition, by M. ization, edited by Roger J. Laham, MD, and Gabriel Khan, MD, FRCP, 2007 Donald S. Baim, MD, 2005 Therapeutic Lipidology, edited by Michael H. David- Interventional Cardiology: Percutaneous son, MD, Kevin C. Maki, PhD, and Peter P. Toth, Noncoronary Intervention, edited by MD, PhD, 2007 Howard C. Herrmann, MD, 2005 Essentials of Restenosis: For the Interventional Principles of Molecular Cardiology, edited by Marschall Cardiologist, edited by Henricus J. Duckers, PhD, MD, Patrick W. Serruys, MD, and Elizabeth S. Runge, MD, and Cam Patterson, MD, 2005 Heart Disease Diagnosis and Therapy: A Practical G. Nabel, MD, 2007 Approach, Second Edition, by M. Gabriel Khan, Cardiac Drug Therapy, Seventh Edition, by M. Gabriel Khan, MD, FRCP(LONDON) , FRCP(C), FACP, FACC, 2007 MD, FRCP(LONDON), FRCP(C), FACP, FACC, 2005 Cardiovascular Genomics: Gene Mining for Cardiovascular Magnetic Resonance Imaging, Pharmacogenomics and Gene Therapy, edited by Raymond Y. Kwong, MD, 2007 Essential Echocardiography: A Practical Handbook edited by Mohan K. Raizada, PhD, Julian F. With DVD, edited by Scott D. Solomon, MD, R. Paton, PhD, Michael J. Katovich, PhD, and 2007 Sergey Kasparov, MD, PhD, 2005 Management of Acute Pulmonary Embolism, Surgical Management of Congestive Heart Failure, edited by Stavros Konstantinides, MD, 2007 edited by James C. Fang, MD Stem Cells and Myocardial Regeneration, edited and Gregory S. Couper, MD, 2005 by Marc S. Penn, MD, PhD, 2007 Cardiopulmonary Resuscitation, edited by Joseph P. Handbook of Complex Percutaneous Carotid Ornato, MD, FACP, FACC, FACEP and Mary Ann Intervention, edited by Jacqueline Saw, MD, Peberdy, MD, FACC, 2005 Jose Exaire, MD, David S. Lee, MD, Sanjay CT of the Heart: Principles and Applications, edited Yadav, MD, 2007 by U. Joseph Schoepf, MD, 2005 Preventive Cardiology: Insights Into the Prevention Coronary Disease in Women: Evidence-Based Diag- and Treatment of Cardiovascular Disease, nosis and Treatment, edited by Leslee J. Shaw, Second Edition, edited by JoAnne Micale PhD and Rita F. Redberg, MD, FACC, 2004 Foody, MD, 2006 Cardiac Transplantation: The Columbia University The Art and Science of Cardiac Physical Medical Center/New York-Presbyterian Examination: With Heart Sounds and Pulse Hospital Manual, edited by Niloo M. Edwards, Wave Forms on CD, by Narasimhan MD, Jonathan M. Chen, MD, and Pamela A. Ranganathan, MD, Vahe Sivaciyan, MD, Mazzeo, 2004 and Franklin B. Saksena, MD, 2006 Heart Disease and Erectile Dysfunction, edited by Cardiovascular Biomarkers: Pathophysiology and Disease Management, edited by David A. Robert A. Kloner, MD, PhD, 2004 Complementary and Alternative Cardiovascular Morrow, MD, 2006 Cardiovascular Disease in the Elderly, edited by Medicine, edited by Richard A. Stein, MD Gary Gerstenblith, MD, 2005 and Mehmet C. Oz, MD, 2004 Nuclear Cardiology, The Basics: How to Set Up Platelet Function: Assessment, Diagnosis, and Treatment, edited by Martin Quinn, MB BCh and Maintain a Laboratory, by Frans J. Th. BAO, PhD, and Desmond Fitzgerald, MD, FRCPI, Wackers, MD, PhD, Wendy Bruni, BS, CNMT, FESC, APP, 2005 and Barry L. Zaret, MD, 2004 C D T ARDIAC RUG HERAPY Seventh Edition by M. G K , , , ABRIEL HAN MD FRCP FACC Associate Professor of Medicine, University of Ottawa, and Cardiologist, The Ottawa Hospital, Ottawa, Ontario, Canada © 2007 Humana Press Inc. 999 Riverview Drive, Suite 208 Totowa, New Jersey 07512 www.humanapress.com All rights reserved. No part of this book may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording, or otherwise without written permission from the Publisher. The content and opinions expressed in this book are the sole work of the authors and editors, who have warranted due diligence in the creation and issuance of their work. The publisher, editors, and authors are not responsible for errors or omissions or for any consequences arising from the information or opinions presented in this book and make no warranty, express or implied, with respect to its contents. Due diligence has been taken by the publishers, editors, and authors of this book to assure the accuracy of the information published and to describe generally accepted practices. The contributors herein have carefully checked to ensure that the drug selections and dosages set forth in this text are accurate and in accord with the standards accepted at the time of publication. Notwithstanding, as new research, changes in government regulations, and knowledge from clinical experience relating to drug therapy and drug reactions constantly occurs, the reader is advised to check the product information provided by the manufacturer of each drug for any change in dosages or for additional warnings and contraindications. This is of utmost importance when the recommended drug herein is a new or infrequently used drug. It is the responsibility of the treating physician to determine dosages and treatment strategies for individual patients. Further it is the responsibility of the health care provider to ascertain the Food and Drug Administration status of each drug or device used in their clinical practice. The publisher, editors, and authors are not responsible for errors or omissions or for any consequences from the application of the information presented in this book and make no warranty, express or implied, with respect to the contents in this publication. For additional copies, pricing for bulk purchases, and/or information about other Humana titles, contact Humana at the above address or at any of the following numbers: Tel.: 973-256-1699; Fax: 973-256-8341, E-mail: [email protected]; or visit our Website: www.humanapress.com This publication is printed on acid-free paper. ∞ ANSI Z39.48-1984 (American National Standards Institute) Permanence of Paper for Printed Library Materials. Photocopy Authorization Policy: Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by Humana Press Inc., provided that the base fee of US $30.00 is paid directly to the Copyright Clearance Center at 222 Rosewood Drive, Danvers, MA 01923. For those organizations that have been granted a photocopy license from the CCC, a separate system of payment has been arranged and is acceptable to Humana Press Inc. The fee code for users of the Transactional Reporting Service is: [978-1-58829-904-8 • 1-58829-904-X/07 $30.00]. Printed in the United States of America. 10 9 8 7 6 5 4 3 2 1 eISBN 1-59745-238-6 ISBN13 978-1-58829-904-8 Library of Congress Cataloging-in-Publication Data Khan, M. I. Gabriel. Cardiac drug therapy / by M. Gabriel Khan. — 7th ed. p. ; cm. — (Contemporary cardiology) Includes bibliographical references and index. ISBN-13: 978-1-58829-904-8 (alk. paper) ISBN-10: 1-58829-904-X (alk. paper) 1. Cardiovascular agents. 2. Heart—Diseases—Chemotherapy. I. Title. II. Series: Contemporary cardiology (Totowa, N.J. : Unnumbered) [DNLM: 1. Heart Diseases—drug therapy—Handbooks. 2. Cardiovascular Agents—therapeutic use— Handbooks. WG 39 K45c 2007] RC684.C48K437 2007 616.1’2061—dc22 2006032373 D EDICATION To My wife Brigid and To our children Susan, Christine, Yasmin, Stephen, Jacqueline, and Natasha v P REFACE The impetus to provide a seventh edition of Cardiac Drug Therapy was generated by the positive comments received from readers worldwide, and from favorable reviews of earlier editions. The seventh edition updates and revises the sixth edition in several respects. In particular, the text includes: Six new chapters that deal with ongoing impor- tant controversies regarding the use of several widely used cardiac drugs. Controversies have arisen regarding the use of beta blockers for the treatment of hypertension. The front cover of The Lancet November 4, 2005 highlighted “beta block- ers should not remain first choice in the treatment of primary hypertension.” Is this statement true or false? In addition Trialists have indicated that beta blockers and diurectics cause an increased incidence of new diabetes; it appears that most experts in the field have endorsed this information. In the Lancet, January 2007, another faulty metaanalysis provides the same misleading information. • The chapter Beta-Blocker Controversies gives substantial evidence that indicates to Clinicians that both preceding statements are false. In the chapter Beta-blockers, a section is given entitled “Which Beta Blocker is Best for Your Patients?” New chapters include: • ACE Inhibitor Controversies. • Calcium Antagonist Controversies: The controversies regarding the use of calcium antagonists are further analyzed and clear directions are given to clinicians regard- ing when to choose a calcium antagonist, and which one to choose. • Hypertension Controversies. There are more than one billion hypertensive indi- viduals requiring drug therapy and only four classes of antihypertensive agents are available: diuretics, beta blockers, ACE inhibitors/angiotensin receptor blockers, and calcium antagonists. Alpha blockers and centrally acting agents have limited use. If it is true that both beta blockers and diuretics cause an increased incidence of new onset diabetes, then patient treatment would be compromised. Physicians worldwide are perplexed. This important area is clarified and treatment algorithms are given for the choice of drug based on the age and ethnicity of the hypertensive patient. • The chapter Heart Failure Controversies discusses : heart failure preserved ejection fraction; is the combination of ACE inhibitor or ARB genuinely beneficial ? Rec- ommended heart failure agents all cause bothersome lowering of blood pressure. Digoxin has been discarded by most who fail to recall that this is the only heart failure drug that does not lower blood pressure, and it can be used without causing toxicity because salutary effects are obtained with low serum digoxin levels 0.5– 0.9 ng/mL particularly in patients with class III-IV heart failure. • The chapter Statin Controversies explores rhabdomyolysis , interactions, and other issues. • The chapter Hallmark Clinical Trials has been expanded to accommodate the wealth of practical information derived from these studies. vii viii Preface As in all previous editions, therapeutic strategies and advice are based on a thorough review of the scientific literature, applied logically: • Scientific documentation regarding which drugs are superior. • Information on which cardiovascular drugs to choose and which agents to avoid in various clinical situations. • Information that assists with the rapid writing of prescriptions. To write a prescrip- tion accurately, a practitioner needs to know how a drug is supplied and its dosage. Thus, supply and dosage are given first, followed by action and pharmacokinetics, then advice as to efficacy and comparison with other drugs, indications, adverse effects, and interactions. • The name of each drug, the formulation, and the dosage have been put in tabular format; this allows quick retrieval of the information required when writing pre- scriptions. • An appendix provides a global table of cardioactive drugs with their generic and tradenames in North America, the UK, Europe, and Japan. • The text contains practical advice, such as the following: The life-saving potential of 75–160 mg chewable aspirin is denied to many individuals who succumb to an acute coronary syndrome because of poor dissemi- nation of clinically proven, documented facts. The text advises: two ~ 80 mg chew- able aspirins should be placed in the cap of a nitrolingual spray container to be used before proceeding to an emergency room. Clinicians should inform patients that rapidly acting chewable aspirin may prevent a heart attack or death but that nitro- glycerin does not. The dosages of drugs given in the text apply to the adult and are standard. Often, a lower dose than the manufacturer’s recommended maximum is advised because in clinical practice a lesser dose suffices and results in fewer adverse effects, espe- cially when medications are combined. The information provided in the seventh edition should serve as a refresher for cardi- ologists and internists. The information should improve the prescribing skills of medical residents, general practitioners, and all who care for patients with cardiac problems. Acknowedgments: First to Paul Dolgert Publishing Director at Humana Press, whom I sought to publish this work because he is without equal at his craft. He has made my book Heart Disease Diagnosis and Therapy a success and has agreed to do more for Rapid ECG Interpretation to be published in 2008. I thank him particularly for agreeing to display my material in a more user friendly format than that of the sixth edition. The pages are wider and the font enlarged. Now, crucial information can be rapidly retrieved and I feel fulfilled. Also, to James Geronimo who expertly guided me through the production concerns and to Lisa Bargeman. Lastly, a special, thank you, to my wife Brigid, who has allowed me to be a student of the science of Medicine to this day. M. Gabriel Khan, MD C ONTENTS Dedications ....................................................................................................................v Preface ................................................................................................................. vii About the Author ....................................................................................................... xiii 1 Beta-Blockers: The Cornerstone of Cardiac Drug Therapy ...........1 New Concepts..............................................................................................1 Beta-Receptors............................................................................................4 Mechanism of Action...................................................................................6 Dosage Considerations...............................................................................7 Pharmacologic Properties and Clinical Implications...............................8 Salutary Effects of Beta-Adrenergic Blockade ........................................13 Beta-Blockers versus Calcium Antagonists and Oral Nitrates...............15 Indications for Beta-Blockers...................................................................16 Advice and Adverse Effects.......................................................................20 Individual Beta-Blockers..........................................................................23 Which Beta-Blocker Is Best for Your Patients?.......................................31 2 Beta-Blocker Controversies............................................................37 Beta-Blockers Are Not a Good Initial Choice for Hypertension: True or False? ................................................................................37 Beta-Blockers Are Not Recommended for Treatment of Elderly Hypertensives: True or False? ......................................38 Beta-Blockers Cause Diabetes: True or False? ......................................39 Do All Beta-Blockers Cause Glucose Intolerance?.................................40 Beta-Blockers Should Not Be Given to Patients During the Early Hours of Acute MI: True or False?...............................41 3 Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers..............................................43 Mechanism of Action.................................................................................43 ACE Inhibitors versus Other Vasodilators ..............................................46 Clinical Indications...................................................................................47 Contraindications......................................................................................50 Advice, Adverse Effects, and Interactions................................................51 Individual ACE Inhibitors.........................................................................53 Angiotensin II Receptor Blockers.............................................................58 4 ACE Inhibitor Controversies..........................................................63 ACE Inhibitors versus ARBS: Does the Choice Matter?.........................63 ACE Inhibitors/ARBs Cause Renoprotection: True or False?................63 ACE Inhibitors Decrease the Incidence of Diabetes: True or False?....64 Combination of ACE Inhibitor and ARB Proven Effective: True or False? ................................................................................64 ACE Inhibitors for HF with Preserved Systolic Function.......................65 5 Calcium Antagonists (Calcium Channel Blockers).......................67 Mechanism of Action.................................................................................67 ix